Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.34 |
| ▸ | RNMT | O43148 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765877 | 0.98 | TYMP (0.39) | TYMPADORA3ADORA2BADORA1PRKAG1 | |
| SCHEMBL3727493 | 0.94 | TYMP (0.42) | TYMPADORA3ADORA2BADORA1PRKAG1 | |
| SCHEMBL21073914 | 0.93 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL667192 | 0.93 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29557743 | 0.93 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL23668111 | 0.93 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21073979 | 0.91 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL20691430 | 0.91 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21305113 | 0.91 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18927161 | 0.91 | TYMP (0.41) | TYMPADORA1PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2540734-B1 | Process and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8063198-B2 | Processes and reagents for desilylation of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8058448-B2 | Processes and reagents for sulfurization of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110196145-A1 | PROCESS FOR DESILYLATION OF OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20050267300-A1 | Processes and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196145-A1 | PROCESS FOR DESILYLATION OF OLIGONUCLEOTIDES | ALKBH1, DIMT1, RNGTT | TYMP 36/4885ADORA3 103/4885ADORA2B 200/4885 |
| US-20050267300-A1 | Processes and reagents for oligonucleotide synthesis and purification | RNGTT, ALKBH1, MTAP | TYMP 26/4885ADORA3 111/4885ADORA2B 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.